Advertisement
ABBV vs NVS
Which Stock Would AI Choose? AbbVie (ABBV) vs. Novartis (NVS) Stock Comparison
Key Takeaways
- AbbVie (ABBV) and Novartis (NVS) are both large-cap pharmaceutical companies with strong dividend histories and exposure to immunology, oncology, and specialty medicines.
- In recent market activity, ABBV has delivered YTD returns of approximately 16% and 1-year returns near 40%, slightly outpacing NVS’s YTD returns of about 15% and 1-year returns around 35%.
- Both stocks benefited from positive earnings developments in recent weeks, with ABBV highlighting an upbeat 2026 outlook and NVS reporting a Q2 earnings beat driven by key products such as Kisqali and Leqvio.
- ABBV exhibits higher volatility tied to its concentrated immunology portfolio, while NVS offers greater diversification across therapeutic areas and a lower beta, reflecting more defensive characteristics.
- Sector sentiment remains constructive for both amid pipeline progress, though ABBV faces minor trial setbacks offset by analyst upgrades and NVS contends with sales pressure on legacy products.
- Relative performance favors ABBV on momentum metrics in the recent period, while NVS provides stability for investors prioritizing lower drawdown risk.
Introduction
AbbVie (ABBV) and Novartis (NVS) represent two prominent players in the global pharmaceutical sector, each navigating patent expirations, pipeline innovation, and evolving healthcare dynamics. This comparison examines their business models, recent stock behavior, and relative positioning in the current market environment. Institutional investors, dividend-focused traders, and those seeking healthcare sector exposure may find the analysis useful for evaluating portfolio allocation decisions between two established names with differing growth profiles and risk exposures.
AbbVie Overview and Recent Performance
AbbVie develops and markets specialty medicines, with a primary focus on immunology through products such as Skyrizi and Rinvoq, alongside oncology and neuroscience offerings. In recent market activity, the stock has shown resilience, closing near $259 on July 24, 2026, after periods of positive momentum supported by an upgraded 2026 earnings outlook and analyst optimism. Performance has been influenced by strong contributions from newer immunology assets offsetting legacy product challenges, resulting in YTD gains near 16% and 1-year returns exceeding 40%. Sentiment has remained constructive despite isolated trial setbacks, as investors emphasize durable earnings growth and pipeline execution in recent weeks.
Novartis Overview and Recent Performance
Novartis operates as a diversified pharmaceutical company with strengths in oncology, cardiovascular, and neuroscience franchises, including drugs such as Kisqali and Leqvio. In recent market activity, the stock closed at approximately $155 on July 24, 2026, following a Q2 earnings beat that exceeded estimates on both revenue and EPS, even as certain legacy products faced sales declines. The company reiterated full-year guidance for low-single-digit sales growth. Performance reflects steady innovation-driven gains, with YTD returns near 15% and 1-year returns around 35%. Sentiment has been supported by pipeline catalysts and regulatory progress, balanced against broader sector pressures in recent weeks.
Trending AI Robots
Tickeron maintains a curated Trending AI Robots section that highlights select AI trading bots from its extensive library of hundreds of automated strategies. These bots trade thousands of different tickers across equities, with only the highest-performing and most suitable options for prevailing market conditions featured in the trending area. Available bots span a wide range of trading styles, timeframes from intraday to longer-term, and performance metrics, including annualized returns that have reached levels such as 54% or higher in documented simulations, alongside varying Sharpe ratios, profit factors, and drawdown profiles. All strategies incorporate distinct risk parameters and ticker sets. Traders interested in exploring these options can review the full selection on the Trending AI Robots page.
Head-to-Head Comparison
AbbVie (ABBV) centers on high-margin immunology and oncology assets with a more concentrated portfolio, delivering stronger recent momentum and higher total returns over the past year compared with Novartis (NVS). Novartis benefits from broader therapeutic diversification and a lower beta, offering greater stability during market fluctuations. Growth drivers for ABBV include expanding indications for Skyrizi and Rinvoq, while NVS draws from oncology leadership and cardiovascular innovations such as Leqvio. Risk factors differ: ABBV faces higher exposure to single-product concentration and occasional trial volatility, whereas NVS contends with legacy product erosion but maintains a more balanced revenue base. Market sentiment has favored ABBV’s earnings durability narrative in recent weeks, while NVS’s defensive profile appeals to risk-averse positioning amid sector rotation.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative momentum, and earnings visibility in recent market activity, Tickeron’s AI would currently assign a probabilistic preference to AbbVie (ABBV) over Novartis (NVS). ABBV’s stronger YTD and 1-year returns, combined with an upgraded forward outlook, suggest more sustained upward trajectory and catalyst alignment. NVS remains competitive on stability metrics and diversification, potentially suiting conservative allocations. This assessment reflects pattern recognition across performance data rather than directional certainty.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a StrongBuy and NVS is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 3 FA rating(s) are green whileNVS’s FA Score has 3 green FA rating(s).
- ABBV’s FA Score: 3 green, 2 red.
- NVS’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 4 TA indicator(s) are bullish while NVS’s TA Score has 3 bullish TA indicator(s).
- ABBV’s TA Score: 4 bullish, 3 bearish.
- NVS’s TA Score: 3 bullish, 5 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +1.39% price change this week, while NVS (@Pharmaceuticals: Major) price change was -3.49% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.23%. For the same industry, the average monthly price growth was +0.30%, and the average quarterly price growth was +2.34%.
Reported Earning Dates
ABBV is expected to report earnings on Oct 23, 2026.
NVS is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.23% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| ABBV | NVS | ABBV / NVS | |
| Capitalization | 441B | 286B | 154% |
| EBITDA | 16.9B | 22.5B | 75% |
| Gain YTD | 11.759 | 12.744 | 92% |
| P/E Ratio | 70.47 | 22.79 | 309% |
| Revenue | 62.8B | 56.7B | 111% |
| Total Cash | N/A | 7.69B | - |
| Total Debt | 72.9B | 49B | 149% |
ABBV | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 23 | 61 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 36 Fair valued | 6 Undervalued | |
PROFIT vs RISK RATING 1..100 | 7 | 7 | |
SMR RATING 1..100 | 1 | 34 | |
PRICE GROWTH RATING 1..100 | 30 | 51 | |
P/E GROWTH RATING 1..100 | 80 | 26 | |
SEASONALITY SCORE 1..100 | 49 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (6) in the Pharmaceuticals Major industry is in the same range as ABBV (36). This means that NVS’s stock grew similarly to ABBV’s over the last 12 months.
NVS's Profit vs Risk Rating (7) in the Pharmaceuticals Major industry is in the same range as ABBV (7). This means that NVS’s stock grew similarly to ABBV’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is somewhat better than the same rating for NVS (34). This means that ABBV’s stock grew somewhat faster than NVS’s over the last 12 months.
ABBV's Price Growth Rating (30) in the Pharmaceuticals Major industry is in the same range as NVS (51). This means that ABBV’s stock grew similarly to NVS’s over the last 12 months.
NVS's P/E Growth Rating (26) in the Pharmaceuticals Major industry is somewhat better than the same rating for ABBV (80). This means that NVS’s stock grew somewhat faster than ABBV’s over the last 12 months.
| ABBV | NVS | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 61% | 2 days ago 49% |
| Momentum ODDS (%) | 2 days ago 43% | 2 days ago 51% |
| MACD ODDS (%) | 2 days ago 47% | 2 days ago 43% |
| TrendWeek ODDS (%) | 2 days ago 63% | 2 days ago 43% |
| TrendMonth ODDS (%) | 2 days ago 65% | 2 days ago 50% |
| Advances ODDS (%) | 5 days ago 60% | 19 days ago 52% |
| Declines ODDS (%) | 12 days ago 48% | 2 days ago 44% |
| BollingerBands ODDS (%) | 2 days ago 60% | 2 days ago 32% |
| Aroon ODDS (%) | 2 days ago 60% | 3 days ago 42% |
Advertisement
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with NVS. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then NVS could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | -0.54% | ||
| NVS - ABBV | 51% Loosely correlated | -0.55% | ||
| BMY - ABBV | 49% Loosely correlated | -1.27% | ||
| JNJ - ABBV | 47% Loosely correlated | -0.66% | ||
| MRK - ABBV | 46% Loosely correlated | +0.21% | ||
| AMGN - ABBV | 46% Loosely correlated | -0.63% | ||
More | ||||